NL-OMON43649已完成4 期
BIOFLOW-V: BIOTRONIK * A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions * V - BIOFLOW-V
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Biotronik
- 入组人数
- 17
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1.Subject is *18 years or the minimum age required for legal adult consent in the country of enrollment.
- •2.Subject is an acceptable candidate for PCI.
- •3.Subject is an acceptable candidate for CABG.
- •4.Subject has clinical evidence of ischemic heart disease, stable or unstable angina pectoris or documented silent ischemia.
- •5.Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either, clopidogrel, prasugrel, ticagrelor or ticlopidine.
- •6.Subject has provided written informed consent.
- •7.Subject is willing to comply with study follow-up requirements.
排除标准
- •1.Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure.
- •2.Subject is hemodynamically unstable.
- •3.Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study.
- •4.Subject has a known allergy to contrast medium that cannot be adequately pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA, sirolimus or everolimus.
- •5.Revascularization of any target vessel within 9 months prior to the index procedure or previous PCI of any non-target vessel within 30 days prior to the index procedure.
- •6.Planned treatment of a lesion not meeting angiographic inclusion and exclusion criteria during the index procedure or after the index procedure.
- •7.Planned surgery within 6 months of index procedure unless dual antiplatelet therapy can be maintained throughout the peri-surgical period.
- •8.History of a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure.
- •9.Subjects with active bleeding disorders, active coagulopathy, or any other reason, who are ineligible for DAPT.
- •10.Subject will refuse blood transfusions.
- •11.Subject has documented left ventricular ejection fraction (LVEF) < 30% as evaluated by angiography, echocardiogram, radionuclide ventriculography or any non-invasive imaging method within 90 days prior to the index procedure.
- •12.Subject is dialysis-dependent.
- •13.Subject has impaired renal function (i.e., blood creatinine > 2.5 mg/dL or 221 *mol/L determined within 7 days prior to the index procedure).
- •14.Subject has leukopenia (i.e. < 3,000 white blood cells/mm3), thrombocytopenia (i.e. < 100,000 platelets/mm3) or thrombocytosis (i.e. > 700,000 platelet/mm3).
- •15.Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted), or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted).
- •16.Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban, rivaroxaban or any other agent).
- •17.Subject has life expectancy of < 1 year.
- •18.Subject is participating in another investigational (medical device or drug) clinical study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.
- •19.In the investigator*s opinion, subject will not be able to comply with the follow-up requirements.
研究者
相似试验
已完成
4 期
BIOTRONIK- *A Prospective, Randomized, Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Stent in the Treatment Of Subjects With up to two de novo Coronary Artery Lesions* - IVcoronary stenosisnarrowing of the arteries which supply the heart with blood1001108210003216NL-OMON44708Biotronik83
已完成
4 期
A prospective randomised controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (CSC).Chronic central serous chorioretinopathy10047060NL-OMON39842niversitair Medisch Centrum119
已完成
不适用
Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of careJuvenile Idiopathic ArthritisNL-OMON38373niversitair Medisch Centrum Utrecht450
已完成
4 期
A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT).NL-OMON52323BIOTRONIK AG1
已完成
不适用
A multicentre Prospective study in pAtients undergoing ventral herNia repair by open approach with intrA-peritoneal positioning using parietex* Composite vEntral pAtch.hernia / abdominal wall defect10041297NL-OMON40149Covidien8